For years, scientists and policy makers have been trying to address two improbably linked problems that hinge on a single radioactive isotope: how to reduce the risk of nuclear weapons proliferation, and how to assure supplies of a material used in thousands of heart, kidney and breast

They seemed to be getting close to a solution. But now General Electric, the company that developed a technology for carrying it out, has quietly dropped work on the project, saying it is not commercially viable.

The isotope is technetium 99m, or tech 99 for short. It is useful in diagnostic tests because it throws off an easy-to-detect gamma ray; also, because it breaks down very quickly, it gives only a small dose of radiation to the patient.

But the recipe for tech 99 requires another isotope, molybdenum 99, that is now made in nuclear reactors using weapon-grade uranium. In May 2009, a Canadian reactor that makes most of the North American supply of moly 99 was shut because of a safety problem. A second reactor, in the Netherlands, was simultaneously closed for repairs.